vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and PJT Partners Inc. (PJT). Click either name above to swap in a different company.
PJT Partners Inc. is the larger business by last-quarter revenue ($531.4M vs $284.0M, roughly 1.9× ACADIA PHARMACEUTICALS INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 10.0%, a 86.3% gap on every dollar of revenue. On growth, PJT Partners Inc. posted the faster year-over-year revenue change (12.9% vs 9.4%). Over the past eight quarters, PJT Partners Inc.'s revenue compounded faster (27.5% CAGR vs 17.5%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
PJT Partners, Inc. is a global advisory-focused investment bank, founded in October 2015 as part of The Blackstone Group's spin-off of its financial and strategic advisory services businesses.
ACAD vs PJT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $531.4M |
| Net Profit | $273.6M | $53.4M |
| Gross Margin | 90.8% | — |
| Operating Margin | 6.1% | 23.1% |
| Net Margin | 96.3% | 10.0% |
| Revenue YoY | 9.4% | 12.9% |
| Net Profit YoY | 90.3% | 4.0% |
| EPS (diluted) | $1.61 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $531.4M | ||
| Q3 25 | $278.6M | $442.3M | ||
| Q2 25 | $264.6M | $401.1M | ||
| Q1 25 | $244.3M | $321.9M | ||
| Q4 24 | $259.6M | $470.5M | ||
| Q3 24 | $250.4M | $320.3M | ||
| Q2 24 | $242.0M | $358.1M | ||
| Q1 24 | $205.8M | $327.1M |
| Q4 25 | $273.6M | $53.4M | ||
| Q3 25 | $71.8M | $39.8M | ||
| Q2 25 | $26.7M | $32.9M | ||
| Q1 25 | $19.0M | $54.0M | ||
| Q4 24 | $143.7M | $51.3M | ||
| Q3 24 | $32.8M | $22.1M | ||
| Q2 24 | $33.4M | $28.3M | ||
| Q1 24 | $16.6M | $32.6M |
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — | ||
| Q1 24 | 88.8% | — |
| Q4 25 | 6.1% | 23.1% | ||
| Q3 25 | 12.8% | 20.6% | ||
| Q2 25 | 12.2% | 19.1% | ||
| Q1 25 | 7.9% | 16.3% | ||
| Q4 24 | 59.1% | 21.9% | ||
| Q3 24 | 12.6% | 15.4% | ||
| Q2 24 | 12.6% | 18.0% | ||
| Q1 24 | 7.4% | 16.5% |
| Q4 25 | 96.3% | 10.0% | ||
| Q3 25 | 25.8% | 9.0% | ||
| Q2 25 | 10.1% | 8.2% | ||
| Q1 25 | 7.8% | 16.8% | ||
| Q4 24 | 55.4% | 10.9% | ||
| Q3 24 | 13.1% | 6.9% | ||
| Q2 24 | 13.8% | 7.9% | ||
| Q1 24 | 8.0% | 10.0% |
| Q4 25 | $1.61 | — | ||
| Q3 25 | $0.42 | — | ||
| Q2 25 | $0.16 | — | ||
| Q1 25 | $0.11 | — | ||
| Q4 24 | $0.86 | — | ||
| Q3 24 | $0.20 | — | ||
| Q2 24 | $0.20 | — | ||
| Q1 24 | $0.10 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $538.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $308.2M |
| Total Assets | $1.6B | $1.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $538.9M | ||
| Q3 25 | $258.0M | $400.5M | ||
| Q2 25 | $253.6M | $214.6M | ||
| Q1 25 | $217.7M | $194.3M | ||
| Q4 24 | $319.6M | $483.9M | ||
| Q3 24 | $155.1M | $148.8M | ||
| Q2 24 | $177.1M | $164.2M | ||
| Q1 24 | $204.7M | $215.5M |
| Q4 25 | $1.2B | $308.2M | ||
| Q3 25 | $917.3M | $228.6M | ||
| Q2 25 | $822.4M | $167.4M | ||
| Q1 25 | $765.2M | $148.8M | ||
| Q4 24 | $732.8M | $187.0M | ||
| Q3 24 | $577.2M | $159.1M | ||
| Q2 24 | $516.7M | $133.8M | ||
| Q1 24 | $464.0M | $174.6M |
| Q4 25 | $1.6B | $1.8B | ||
| Q3 25 | $1.3B | $1.7B | ||
| Q2 25 | $1.2B | $1.5B | ||
| Q1 25 | $1.1B | $1.4B | ||
| Q4 24 | $1.2B | $1.6B | ||
| Q3 24 | $976.9M | $1.6B | ||
| Q2 24 | $914.1M | $1.4B | ||
| Q1 24 | $855.1M | $1.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $155.7M |
| Free Cash FlowOCF − Capex | — | $138.6M |
| FCF MarginFCF / Revenue | — | 26.1% |
| Capex IntensityCapex / Revenue | — | 3.2% |
| Cash ConversionOCF / Net Profit | -0.18× | 2.92× |
| TTM Free Cash FlowTrailing 4 quarters | — | $480.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $155.7M | ||
| Q3 25 | $74.3M | $256.1M | ||
| Q2 25 | $64.0M | $190.4M | ||
| Q1 25 | $20.3M | $-75.9M | ||
| Q4 24 | $40.4M | $195.7M | ||
| Q3 24 | $63.2M | $180.5M | ||
| Q2 24 | $25.0M | $193.6M | ||
| Q1 24 | $29.1M | $-38.8M |
| Q4 25 | — | $138.6M | ||
| Q3 25 | $73.9M | $240.9M | ||
| Q2 25 | — | $178.9M | ||
| Q1 25 | — | $-77.9M | ||
| Q4 24 | — | $195.3M | ||
| Q3 24 | $63.2M | $178.5M | ||
| Q2 24 | — | $193.0M | ||
| Q1 24 | — | $-39.2M |
| Q4 25 | — | 26.1% | ||
| Q3 25 | 26.5% | 54.5% | ||
| Q2 25 | — | 44.6% | ||
| Q1 25 | — | -24.2% | ||
| Q4 24 | — | 41.5% | ||
| Q3 24 | 25.2% | 55.7% | ||
| Q2 24 | — | 53.9% | ||
| Q1 24 | — | -12.0% |
| Q4 25 | — | 3.2% | ||
| Q3 25 | 0.1% | 3.4% | ||
| Q2 25 | — | 2.9% | ||
| Q1 25 | — | 0.6% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | 0.0% | 0.6% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 0.1% |
| Q4 25 | -0.18× | 2.92× | ||
| Q3 25 | 1.03× | 6.43× | ||
| Q2 25 | 2.40× | 5.79× | ||
| Q1 25 | 1.07× | -1.41× | ||
| Q4 24 | 0.28× | 3.81× | ||
| Q3 24 | 1.93× | 8.15× | ||
| Q2 24 | 0.75× | 6.84× | ||
| Q1 24 | 1.76× | -1.19× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
PJT
Segment breakdown not available.
